Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call
The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2677066. To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.
About
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in INVELTYS® which received
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005810/en/
Source:
Investor:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
Media:
Kari Watson
kwatson@macbiocom.com
781-235-3060